Review





Similar Products

18 f-z her2:342 -affibody  (Affibody)
90
Affibody 18 f-z her2:342 -affibody
18 F Z Her2:342 Affibody, supplied by Affibody, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/18 f-z her2:342 -affibody/product/Affibody
Average 90 stars, based on 1 article reviews
18 f-z her2:342 -affibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
18 fz her2:342 -affibody binding  (Affibody)
90
Affibody 18 fz her2:342 -affibody binding
18 Fz Her2:342 Affibody Binding, supplied by Affibody, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/18 fz her2:342 -affibody binding/product/Affibody
Average 90 stars, based on 1 article reviews
18 fz her2:342 -affibody binding - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
18 f-z her2:342  (Affibody)
90
Affibody 18 f-z her2:342
Contiguous axial <t>PET/MRI</t> sections of mouse 2 collected 9 and 10 wk after cells injection showing rapid metastasis progression. HER2-positive lung metastases were visualized with high tumor-to-background ratio 1 h after 18F-ZHER2:342-Affibody injection. Tracer uptake 10 wk after cell inoculation, indicated by white arrows, was as follows: 6.2 %ID/g (lesion 1), 6.9 %ID/g (lesion 2), and 3.4 %ID/g (lesion 3). TBR = tumor-to-background ratio.
18 F Z Her2:342, supplied by Affibody, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/18 f-z her2:342/product/Affibody
Average 90 stars, based on 1 article reviews
18 f-z her2:342 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Contiguous axial PET/MRI sections of mouse 2 collected 9 and 10 wk after cells injection showing rapid metastasis progression. HER2-positive lung metastases were visualized with high tumor-to-background ratio 1 h after 18F-ZHER2:342-Affibody injection. Tracer uptake 10 wk after cell inoculation, indicated by white arrows, was as follows: 6.2 %ID/g (lesion 1), 6.9 %ID/g (lesion 2), and 3.4 %ID/g (lesion 3). TBR = tumor-to-background ratio.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Article Title: PET of HER2-Positive Pulmonary Metastases with 18 F-Z HER2:342 Affibody in a Murine Model of Breast Cancer: Comparison with 18 F-FDG

doi: 10.2967/jnumed.111.100354

Figure Lengend Snippet: Contiguous axial PET/MRI sections of mouse 2 collected 9 and 10 wk after cells injection showing rapid metastasis progression. HER2-positive lung metastases were visualized with high tumor-to-background ratio 1 h after 18F-ZHER2:342-Affibody injection. Tracer uptake 10 wk after cell inoculation, indicated by white arrows, was as follows: 6.2 %ID/g (lesion 1), 6.9 %ID/g (lesion 2), and 3.4 %ID/g (lesion 3). TBR = tumor-to-background ratio.

Article Snippet: PET/MRI/CT 18 F-Z HER2:342 -Affibody sufficiently targeted HER2-positive metastatic foci within the lungs approximately 9 wk after inoculation of cells, providing a high tumor-to-background ratio in the animals above the arbitrary luminescence signal threshold (1 × 10 6 [p/s]).

Techniques: Injection